BETA


2013/0222(COD) Medicinal products for human use: fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI MCAVAN Linda (icon: S&D S&D) AYUSO Pilar (icon: PPE PPE)
Committee Opinion ITRE
Committee Opinion IMCO
Lead committee dossier:
Legal Basis:
TFEU 114, TFEU 168-p4

Events

2019/09/30
   EC - Follow-up document
Details

The Commission presented its report on the exercise of the delegation conferred on the Commission pursuant to Regulation (EU) No 658/2014 of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.

Delimitation of the delegation of powers

The Pharmacovigilance Fee Regulation empowers the Commission to adopt delegated acts adjusting the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs, where such adjustment is considered justified in light of an annual monitoring of the inflation rate, measured by means of the European Index of Consumer prices published by Eurostat.

The present report is a requirement under Article 16(2) of the Pharmacovigilance Fee Regulation. This provision delegates powers to the Commission for five years, starting from 17 July 2014. A report on the exercise of the delegation should be drawn up not later than nine months before the end of this period. The delegation of powers is to be tacitly extended for periods of an identical duration, unless the European Parliament or the Council opposes such extension not later than three months before the end of each period.

Exercise of the delegation

To date the Commission has exercised in two instances the delegated powers provided for by Regulation (EU) No 658/2014 to adjust to the inflation the amounts of fees and remuneration laid down in that Regulation :

(1) Delegated act adjusting the amounts laid down in the Pharmacovigilance Fee Regulation taking into account cumulatively the inflation rate of the Union for 2015 and for 2016 :the inflation rate of the Union, as made available by Eurostat, was 0.2 % for 2015 and 1.2 % for 2016. In view of these inflation rates, it was considered justified to proceed to an adjustment in 2017. A cumulative adjustment, taking into account the inflation rates for 2015 and for 2016, was therefore applied. The Commission adopted the Delegated Regulation (EU) 2018/92 which started to apply from 12 February 2018.

(2) Delegated act adjusting the amounts laid down in the Pharmacovigilance Fee Regulation taking into account the inflation rate of the Union for 2017 : the inflation rate of the Union, as made available by Eurostat, was 1.7 % for 2017.

It was considered justified to proceed to an adjustment for 2017. The Commission adopted Delegated Regulation (EU) 2018/1298 which started to apply from 18 October 2018.

2014/07/09
   EC - Commission response to text adopted in plenary
Documents
2014/06/27
   Final act published in Official Journal
Details

PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products.

LEGISLATIVE ACT: Regulation (EU) No 658/2014 of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.

CONTENT: in order to enable the Agency to charge fees for those new pharmacovigilance tasks , and pending an overall legislative revision of the fees regimes in the medicinal products sector, this Regulation has been adopted. The revised 2010 legislation provides for new pharmacovigilance tasks for the Agency, including pharmacovigilance procedures carried out at Union level, the monitoring of literature cases and the improved use of information technology tools.

Subject matter and scope : this Regulation shall apply to fees for pharmacovigilance activities relating to medicinal products for human use authorised in the Union and which shall be levied by the European Medicines Agency on marketing authorisation holders.

Homeopathic and herbal medicinal products registered in accordance with Directive 2001/83/EC, and medicinal products which are authorised to be placed on the market in accordance with Directive 2001/83/EC, shall be excluded from the scope of this Regulation.

This Regulation establishes the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs.

Chargeable unit : a chargeable unit is defined on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof.

Types of fees : the types of fees charged to marketing authorisation holders are as follows:

Fees for the assessment of periodic safety update reports : EUR 19 500 per procedure. From that amount, the remuneration for the rapporteur shall be EUR 13 100. That remuneration shall be shared, where applicable, between the rapporteur and the co-rapporteur(s). Fees for the assessment of post-authorisation safety studies : EUR 43 000 to be paid in two instalments as follows: (a) EUR 17 200 shall be due at the date of the start of the procedure for the assessment of the draft protocol referred to in Directive 2001/83/EC; (b) EUR 25 800 shall be due at the date of the start of the procedure for the assessment of the final study report by the Pharmacovigilance Risk Assessment Committee as referred to in the same Directive. Fees for assessments in the context of referrals initiated as a result of pharmacovigilance data : EUR 179 000 where one or two active substances and/or combinations of active substances are included in the assessment. That fee shall be increased by EUR 38 800 per each additional active substance or combination of active substances as of the third active substance or combination of substances. That fee shall not exceed EUR 295 400 irrespective of the number of active substances and/or combinations of active substances. An annual flat-rate fee of EUR 67 per chargeable unit. This fee is intended to cover the costs of general pharmacovigilance activities of EMA, such as safety data management, literature monitoring and information technology, notably maintenance of the EudraVigilance database. The annual flat fee will be charged as from 1 July 2015 .

Reductions and exonerations : small and medium-sized enterprises will benefit of a fee reduction of 40% from all fees covered by the regulation and micro-enterprises are exempted from any fees. Micro enterprises should be exempted from all fees. Generic medicinal products, medicinal products authorised under the provisions relating to well-established medicinal use, authorised homeopathic medicinal products and authorised herbal medicinal products should be subject to a reduced annual fee .

Transparency : the fees established in this Regulation should be transparent, fair and proportionate to the work carried out. Information on those fees should be publicly available . Any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities.

ENTRY INTO FORCE: 17.07.2014.

DELEGATED ACTS: the Commission shall be empowered to adopt delegated acts in order to adjust the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation. The power to adopt delegated acts shall be conferred on the Commission for a period of five years from 17 July 2014 . The European Parliament or the Council may raise objections to a delegated act within a period of two months from the date of notification (this may be extended by two months). If the European Parliament or Council express objections, the delegated act will not enter into force.

2014/05/15
   CSL - Draft final act
Documents
2014/05/15
   CSL - Final act signed
2014/05/15
   EP - End of procedure in Parliament
2014/05/08
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2014/05/08
   CSL - Council Meeting
2014/04/16
   EP - Results of vote in Parliament
2014/04/16
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted by 544 votes to 17, with 11 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.

Parliament adopted its position at first reading following the ordinary legislative procedure. The amendments adopted in plenary are the result of an agreement reached between the European Parliament and the Council. They amended the proposal as follows:

Subject matter and scope : Parliament and the Council agreed to adopt this Regulation in order to enable the European Medicines Agency (EMA) to charge fees for those new pharmacovigilance tasks, and pending an overall legislative revision of the fees regimes in the medicinal products sector .

This Regulation should establish the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs .

Homeopathic and herbal medicinal products and medicinal products which are authorised to be placed on the market in accordance with Article 126a of Directive 2001/83/EC, should be excluded from the scope of this Regulation.

Definition of chargeable unit : fees should be levied on all marketing authorisation holders on a fair basis. Therefore, a chargeable unit should be established, irrespective of the procedure under which the medicinal product has been authorised, and of the way in which authorisation numbers are assigned by the Member States or the Commission.

That objective is met by establishing the chargeable unit on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof.

The active substance(s) should not be taken into account when establishing the chargeable unit in respect of authorised homeopathic medicinal products or authorised herbal medicinal products.

Types of fees : it is stipulated that where a fee is levied by the Agency, the Agency shall pay remuneration, to the national competent authorities:

for the services provided by the rapporteurs and, where applicable, the co-rapporteurs in the Pharmacovigilance Risk Assessment Committee appointed as members of that Committee by Member States; for the work carried out by the Member States which act as the rapporteurs and, where applicable, co-rapporteurs in the coordination group.

Annual fee : for its pharmacovigilance activities relating to information technology systems and the monitoring of selected medical literature, the Agency should levy once per year a fee. The annual fee should be due on 1 July of every year in respect of that calendar year.

The amended text emphasises the fact that fees should be established on a basis which takes due account of the ability of small and medium-sized enterprises to pay . Moreover, information on those fees should be publicly available.

Where justified, the Commission should adopt delegated acts adjusting the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation.

Lastly, any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities.

Documents
2013/12/20
   EP - Committee report tabled for plenary, 1st reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the report by Linda McAVAN (S&D, UK) on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use

The committee recommended that Parliament’s position in first reading following the ordinary legislative procedure should amend the Commission proposal as follows:

Purpose and scope : an amendment aimed to confirm that homeopathic and registered herbal medicinal should be excluded from the scope of the Regulation.

Members also specified that the Regulation determined the pharmacovigilance activities performed at Union level for which fees were due, the amounts and the rules of payment of those fees and the level of remuneration of the Agency, the rapporteurs and the co-rapporteurs.

In order to ensure a clear separation between fees paid to Member States and fees paid to the European Medicines Agency, Members stated that Member States should not impose fees for pharmacovigilance tasks that are already covered by the Regulation.

Definition of chargeable unit: the Commission proposal had meant that companies would be charged according to the number of different market authorisations they held - and this was calculated down to the size of the pack. Members felt that the number of tablets in a pack was not relevant for pharmacovigilance. It would be more appropriate to charge according to the number of authorisations per active ingredient, and per pharmaceutical form.

Annual flat fee : this had been proposed to cover the costs of other pharmacovigilance activities carried out by the Agency, particularly signal detection.

Members proposed reducing the amount raised by the EMA, and the scope of the flat fee to cover only the tasks to be undertaken by EMA : Eudravigilance, the Article 57 database, PSUR repository and literature review only, turning the flat fee into a maintenance fee for EMA pharmacovigilance work.

To create a level playing field, the reduced annual fee should apply to products with well-established safety profile.

Fee reduction : the marketing authorisation holder claiming or having claimed to be entitled to a reduction or an exemption under the Regulation, should submit to the Agency, within seven calendar days from receipt of the Agency's request, the information necessary to demonstrate compliance with the relevant conditions in order for the Agency to be able to verify that those conditions were fulfilled.

Fees for safety report : Members felt that the variations were a consequence of periodic safety update assessment, should be seen as an integral part of the entire assessment process and not be charged additionally at national level as no second scientific assessment is required.

The committee wanted rapporteurs and co-rapporteurs from Member States to be fairly remunerated, in order to incentivise them to volunteer for the work involved in handling referrals. The corresponding remuneration of the rapporteur and co-rapporteur is 50% of the total fee collected.

Documents
2013/12/17
   EP - Vote in committee, 1st reading
2013/11/11
   EP - Amendments tabled in committee
Documents
2013/11/11
   EP - Amendments tabled in committee
Documents
2013/10/24
   EP - Committee draft report
Documents
2013/10/16
   ESC - Economic and Social Committee: opinion, report
Documents
2013/08/20
   IT_SENATE - Contribution
Documents
2013/07/11
   EP - MCAVAN Linda (S&D) appointed as rapporteur in ENVI
2013/07/01
   EP - Committee referral announced in Parliament, 1st reading
2013/06/26
   EC - Legislative proposal
Details

PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products.

PROPOSED ACT: Regulation of the European Parliament and of the Council.

ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

BACKGROUND: the legal framework of pharmacovigilance for medicinal products for human use marketed within the EU is provided for in Regulation (EC) No 726/2004 and in Directive 2001/83/EC .

Legislation in this area was revised in 2010 through Regulation (EU) No 1235/2010 and Directive 2010/84/EU which strengthen and rationalise the system for safety monitoring of medicines on the European market.

This legislation is applicable as of July 2012. It provides for a number of EU-wide procedures to assess pharmacovigilance data which may lead to regulatory action. Some additional amendments to the pharmacovigilance legislation were introduced in 2012 with Directive 2012/26/EU following the 'Mediator' case.

The revised pharmacovigilance legislation significantly widened the tasks of the European Medicines Agency with regard to pharmacovigilance, irrespective of whether the medicinal products have been authorised via the 'centralised procedure' (in accordance with the Regulation) or via national procedures (in accordance with the Directive). The Agency has therefore acquired pharmacovigilance competences also for nationally authorised medicines, in addition to reinforced competences for centrally authorised medicines.

Other tasks include the monitoring of literature cases, the improved information technology tools and the provision of more information to the general public.

New categories of fees should therefore be created to cover the new and specific tasks of the Agency.

IMPACT ASSESSMENT: the Impact Assessment report that accompanies this proposal considered several options, based on estimation of cost.

A combination of procedure-based fees and an annual flat fee has been considered to be the most transparent, cost-based, activity-based and proportionate way of setting the new fees, in order to cover the cost under the new pharmacovigilance legislation.

LEGAL BASIS: Article 114 and Article 168(4)(c) of the Treaty on the Functioning of the European Union (TFEU).

CONTENT: the proposed Regulation aims at setting high standards of quality and safety for medicinal products as it ensures the availability of sufficient financial resources to perform the pharmacovigilance activities that are necessary to guarantee that high standards are maintained once the product is authorised.

The revised pharmacovigilance legislation provides for fees to be charged to marketing authorisation holders. These fees should be related to pharmacovigilance activities performed at the level of the EU, notably in the context of the EU-wide assessment procedures. These procedures include scientific assessment carried out by rapporteurs from the national competent authorities of the Member States. These fees are therefore not intended to cover the pharmacovigilance activities of the national competent authorities performed at national level. Member States may accordingly continue to charge fees for the activities performed at national level which should, however, not overlap with the fees laid down in this legal proposal.

The proposal foresees two separate types of fees :

fees for procedures for the assessment of periodic safety update reports, postauthorisation safety studies and pharmacovigilance referrals; an annual flat fee to be charged to marketing authorisation holders having at least one medicinal product that is authorised in the EU and registered in the database provided for in Regulation (EC) No 726/2004. The fee revenue from the annual flat fee shall be retained by the Agency.

Some fee reductions and fee waivers are foreseen in respect of the proposed fees:

reductions for medicinal products for which the marketing authorisation holder is a small or medium-sized enterprise would be granted for all types of fees. Micro enterprises would be exempted from all fees; a reduction of the annual flat fee is therefore proposed for authorised generic, homeopathic and herbal medicinal products and for medicinal products authorised on grounds of well-established medical use. However, where these medicinal products are included in the Union-wide pharmacovigilance procedures, the full fees for procedures would apply.

Marketing authorisation holders would be charged as follows:

marketing authorisation holders having at least one product involved in a Unionwide pharmacovigilance procedure would be charged a fee for procedures, marketing authorisation holders in the EU, with the exceptions explained above, would be charged the annual flat fee.

Fees referred to in this Regulation should be transparent, fair and proportionate to the work carried out.

In line with the recommendations of the European Court of Auditors and the European Parliament , it is proposed that rapporteurs from the national competent authorities of the Member States be remunerated according to a fixed scale based on estimations of cost.

BUDGETARY IMPLICATION: all options of legislative action, including the option which underpins this proposal, were based on the assumption that the costs related to pharmacovigilance would be covered through fees.

Therefore, no impact on the EU general budget is foreseen in the accompanying financial statement of this proposal.

DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in in accordance with Article 290 of the Treaty on the Functioning of the European Union.

2013/06/26
   EC - Document attached to the procedure
2013/06/26
   EC - Document attached to the procedure

Documents

Votes

A7-0476/2013 - Linda McAvan - Résolution législative #

2014/04/16 Outcome: +: 544, -: 17, 0: 11
DE FR ES PL GB IT SE PT RO BE HU NL BG SK AT DK CZ EL IE HR FI LT LU SI LV MT EE CY
Total
77
61
44
42
58
31
20
19
18
18
16
25
14
13
16
12
14
11
9
9
8
8
6
6
6
5
3
2
icon: PPE PPE
202

Denmark PPE

For (1)

1

Czechia PPE

2

Luxembourg PPE

3

Malta PPE

For (1)

1

Cyprus PPE

1
icon: S&D S&D
144

Hungary S&D

3

Netherlands S&D

3

Ireland S&D

1

Finland S&D

1

Lithuania S&D

1

Luxembourg S&D

For (1)

1

Slovenia S&D

For (1)

1

Estonia S&D

For (1)

1

Cyprus S&D

1
icon: ALDE ALDE
63

Romania ALDE

1

Slovakia ALDE

For (1)

1
3

Greece ALDE

1

Ireland ALDE

2

Finland ALDE

1

Lithuania ALDE

1

Luxembourg ALDE

For (1)

1

Slovenia ALDE

For (1)

1
2
icon: Verts/ALE Verts/ALE
50

United Kingdom Verts/ALE

4

Portugal Verts/ALE

For (1)

1

Netherlands Verts/ALE

3

Austria Verts/ALE

2

Denmark Verts/ALE

For (1)

1

Finland Verts/ALE

2

Luxembourg Verts/ALE

For (1)

1

Latvia Verts/ALE

1
icon: ECR ECR
39

Italy ECR

1

Netherlands ECR

For (1)

1

Denmark ECR

For (1)

1

Croatia ECR

For (1)

1
icon: GUE/NGL GUE/NGL
28

France GUE/NGL

For (1)

Against (1)

4

Spain GUE/NGL

For (1)

1

United Kingdom GUE/NGL

1

Sweden GUE/NGL

1

Netherlands GUE/NGL

2

Denmark GUE/NGL

For (1)

1

Czechia GUE/NGL

2

Ireland GUE/NGL

For (1)

1

Croatia GUE/NGL

1

Latvia GUE/NGL

For (1)

1
icon: EFD EFD
20

Poland EFD

Abstain (1)

3
4

Netherlands EFD

For (1)

1

Slovakia EFD

For (1)

1

Greece EFD

1

Finland EFD

For (1)

1

Lithuania EFD

For (1)

Abstain (1)

2
icon: NI NI
25

France NI

For (1)

3

Spain NI

1

Italy NI

2

Romania NI

For (1)

1

Belgium NI

Abstain (1)

1

Hungary NI

2

Austria NI

Against (1)

Abstain (1)

4

Ireland NI

For (1)

1
AmendmentsDossier
98 2013/0222(COD)
2013/11/11 ENVI 98 amendments...
source: PE-523.004

History

(these mark the time of scraping, not the official date of the change)

docs/0
date
2013-06-26T00:00:00
docs
summary
type
Legislative proposal
body
EC
docs/2
date
2013-10-16T00:00:00
docs
url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:5169)(documentyear:2013)(documentlanguage:EN) title: CES5169/2013
type
Economic and Social Committee: opinion, report
body
ESC
docs/3
date
2013-10-16T00:00:00
docs
url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:5169)(documentyear:2013)(documentlanguage:EN) title: CES5169/2013
type
Economic and Social Committee: opinion, report
body
ESC
docs/3
date
2013-10-24T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514 title: PE519.514
type
Committee draft report
body
EP
docs/3/docs/0/url
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:5169)(documentyear:2013)(documentlanguage:EN)
New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:5169)(documentyear:2013)(documentlanguage:EN)
docs/4
date
2013-10-24T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514 title: PE519.514
type
Committee draft report
body
EP
docs/4
date
2013-11-11T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004 title: PE523.004
type
Amendments tabled in committee
body
EP
docs/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514
New
https://www.europarl.europa.eu/doceo/document/ENVI-PR-519514_EN.html
docs/5
date
2013-11-11T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004 title: PE523.004
type
Amendments tabled in committee
body
EP
docs/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004
New
https://www.europarl.europa.eu/doceo/document/ENVI-AM-523004_EN.html
events/0
date
2013-07-01T00:00:00
type
Committee referral announced in Parliament, 1st reading/single reading
body
EP
events/0
date
2013-06-26T00:00:00
type
Legislative proposal published
body
EC
docs
summary
events/0/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading
events/1
date
2013-07-01T00:00:00
type
Committee referral announced in Parliament, 1st reading/single reading
body
EP
events/1
date
2013-12-17T00:00:00
type
Vote in committee, 1st reading/single reading
body
EP
events/1/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee, 1st reading
events/2
date
2013-12-17T00:00:00
type
Vote in committee, 1st reading/single reading
body
EP
events/2
date
2013-12-20T00:00:00
type
Committee report tabled for plenary, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-7-2013-0476_EN.html title: A7-0476/2013
summary
events/3
date
2013-12-20T00:00:00
type
Committee report tabled for plenary, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/A-7-2013-0476_EN.html title: A7-0476/2013
summary
events/4
date
2014-04-16T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-7-2014-0438_EN.html title: T7-0438/2014
summary
events/5
date
2014-04-16T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-7-2014-0438_EN.html title: T7-0438/2014
summary
procedure/Modified legal basis
Rules of Procedure EP 159
procedure/Other legal basis
Rules of Procedure EP 159
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: MCAVAN Linda date: 2013-07-11T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
name: AYUSO Pilar group: European People's Party (Christian Democrats) abbr: PPE
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2013-07-11T00:00:00
rapporteur
name: MCAVAN Linda group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
name: AYUSO Pilar group: European People's Party (Christian Democrats) abbr: PPE
docs/7/body
EC
docs/8
date
2019-09-30T00:00:00
docs
summary
type
Follow-up document
body
EC
events/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf
events/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-0476&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-7-2013-0476_EN.html
events/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0438
New
http://www.europarl.europa.eu/doceo/document/TA-7-2014-0438_EN.html
procedure/Modified legal basis
Old
Rules of Procedure EP 150
New
Rules of Procedure EP 159
activities
  • date: 2013-06-26T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf title: COM(2013)0472 type: Legislative proposal published celexid: CELEX:52013PC0472:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio type: Legislative proposal published
  • date: 2013-07-01T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: PPE name: AYUSO Pilar responsible: True committee: ENVI date: 2013-07-11T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • date: 2013-12-17T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP shadows: group: PPE name: AYUSO Pilar responsible: True committee: ENVI date: 2013-07-11T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
  • body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-0476&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0476/2013 type: Committee report tabled for plenary, 1st reading/single reading committees: body: EP shadows: group: PPE name: AYUSO Pilar responsible: True committee: ENVI date: 2013-07-11T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE date: 2013-12-20T00:00:00
  • date: 2014-04-16T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=23897&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0438 type: Decision by Parliament, 1st reading/single reading title: T7-0438/2014 body: EP type: Results of vote in Parliament
  • date: 2014-05-08T00:00:00 body: CSL type: Council Meeting council: Foreign Affairs meeting_id: 3311
  • date: 2014-05-08T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
  • date: 2014-05-15T00:00:00 body: CSL type: Final act signed
  • date: 2014-05-15T00:00:00 body: EP type: End of procedure in Parliament
  • date: 2014-06-27T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658 title: Regulation 2014/658 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:189:TOC title: OJ L 189 27.06.2014, p. 0112
commission
  • body: EC dg: Health and Food Safety commissioner: BORG Tonio
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2013-07-11T00:00:00
rapporteur
name: MCAVAN Linda group: Progressive Alliance of Socialists and Democrats abbr: S&D
shadows
name: AYUSO Pilar group: European People's Party (Christian Democrats) abbr: PPE
committees/0
body
EP
shadows
group: PPE name: AYUSO Pilar
responsible
True
committee
ENVI
date
2013-07-11T00:00:00
committee_full
Environment, Public Health and Food Safety
rapporteur
group: S&D name: MCAVAN Linda
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
opinion
False
committees/1
body
EP
responsible
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
committees/2
type
Committee Opinion
body
EP
associated
False
committee_full
Internal Market and Consumer Protection
committee
IMCO
opinion
False
committees/2
body
EP
responsible
False
committee_full
Industry, Research and Energy
committee
ITRE
council
  • body: CSL type: Council Meeting council: Foreign Affairs meeting_id: 3311 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3311*&MEET_DATE=08/05/2014 date: 2014-05-08T00:00:00
docs
  • date: 2013-06-26T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0234:FIN:EN:PDF title: EUR-Lex title: SWD(2013)0234 type: Document attached to the procedure body: EC
  • date: 2013-06-26T00:00:00 docs: url: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0235:FIN:EN:PDF title: EUR-Lex title: SWD(2013)0235 type: Document attached to the procedure body: EC
  • date: 2013-10-16T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:5169)(documentyear:2013)(documentlanguage:EN) title: CES5169/2013 type: Economic and Social Committee: opinion, report body: ESC
  • date: 2013-10-24T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514 title: PE519.514 type: Committee draft report body: EP
  • date: 2013-11-11T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004 title: PE523.004 type: Amendments tabled in committee body: EP
  • date: 2013-11-11T00:00:00 docs: title: PE523.032 type: Amendments tabled in committee body: EP
  • date: 2014-05-15T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=[%n4]%2F14&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 00044/2014/LEX type: Draft final act body: CSL
  • date: 2014-07-09T00:00:00 docs: url: /oeil/spdoc.do?i=23897&j=0&l=en title: SP(2014)471 type: Commission response to text adopted in plenary
  • date: 2013-08-20T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2013)0472 title: COM(2013)0472 type: Contribution body: IT_SENATE
events
  • date: 2013-06-26T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf title: COM(2013)0472 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2013&nu_doc=472 title: EUR-Lex summary: PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products. PROPOSED ACT: Regulation of the European Parliament and of the Council. ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council. BACKGROUND: the legal framework of pharmacovigilance for medicinal products for human use marketed within the EU is provided for in Regulation (EC) No 726/2004 and in Directive 2001/83/EC . Legislation in this area was revised in 2010 through Regulation (EU) No 1235/2010 and Directive 2010/84/EU which strengthen and rationalise the system for safety monitoring of medicines on the European market. This legislation is applicable as of July 2012. It provides for a number of EU-wide procedures to assess pharmacovigilance data which may lead to regulatory action. Some additional amendments to the pharmacovigilance legislation were introduced in 2012 with Directive 2012/26/EU following the 'Mediator' case. The revised pharmacovigilance legislation significantly widened the tasks of the European Medicines Agency with regard to pharmacovigilance, irrespective of whether the medicinal products have been authorised via the 'centralised procedure' (in accordance with the Regulation) or via national procedures (in accordance with the Directive). The Agency has therefore acquired pharmacovigilance competences also for nationally authorised medicines, in addition to reinforced competences for centrally authorised medicines. Other tasks include the monitoring of literature cases, the improved information technology tools and the provision of more information to the general public. New categories of fees should therefore be created to cover the new and specific tasks of the Agency. IMPACT ASSESSMENT: the Impact Assessment report that accompanies this proposal considered several options, based on estimation of cost. A combination of procedure-based fees and an annual flat fee has been considered to be the most transparent, cost-based, activity-based and proportionate way of setting the new fees, in order to cover the cost under the new pharmacovigilance legislation. LEGAL BASIS: Article 114 and Article 168(4)(c) of the Treaty on the Functioning of the European Union (TFEU). CONTENT: the proposed Regulation aims at setting high standards of quality and safety for medicinal products as it ensures the availability of sufficient financial resources to perform the pharmacovigilance activities that are necessary to guarantee that high standards are maintained once the product is authorised. The revised pharmacovigilance legislation provides for fees to be charged to marketing authorisation holders. These fees should be related to pharmacovigilance activities performed at the level of the EU, notably in the context of the EU-wide assessment procedures. These procedures include scientific assessment carried out by rapporteurs from the national competent authorities of the Member States. These fees are therefore not intended to cover the pharmacovigilance activities of the national competent authorities performed at national level. Member States may accordingly continue to charge fees for the activities performed at national level which should, however, not overlap with the fees laid down in this legal proposal. The proposal foresees two separate types of fees : fees for procedures for the assessment of periodic safety update reports, postauthorisation safety studies and pharmacovigilance referrals; an annual flat fee to be charged to marketing authorisation holders having at least one medicinal product that is authorised in the EU and registered in the database provided for in Regulation (EC) No 726/2004. The fee revenue from the annual flat fee shall be retained by the Agency. Some fee reductions and fee waivers are foreseen in respect of the proposed fees: reductions for medicinal products for which the marketing authorisation holder is a small or medium-sized enterprise would be granted for all types of fees. Micro enterprises would be exempted from all fees; a reduction of the annual flat fee is therefore proposed for authorised generic, homeopathic and herbal medicinal products and for medicinal products authorised on grounds of well-established medical use. However, where these medicinal products are included in the Union-wide pharmacovigilance procedures, the full fees for procedures would apply. Marketing authorisation holders would be charged as follows: marketing authorisation holders having at least one product involved in a Unionwide pharmacovigilance procedure would be charged a fee for procedures, marketing authorisation holders in the EU, with the exceptions explained above, would be charged the annual flat fee. Fees referred to in this Regulation should be transparent, fair and proportionate to the work carried out. In line with the recommendations of the European Court of Auditors and the European Parliament , it is proposed that rapporteurs from the national competent authorities of the Member States be remunerated according to a fixed scale based on estimations of cost. BUDGETARY IMPLICATION: all options of legislative action, including the option which underpins this proposal, were based on the assumption that the costs related to pharmacovigilance would be covered through fees. Therefore, no impact on the EU general budget is foreseen in the accompanying financial statement of this proposal. DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in in accordance with Article 290 of the Treaty on the Functioning of the European Union.
  • date: 2013-07-01T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2013-12-17T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2013-12-20T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-0476&language=EN title: A7-0476/2013 summary: The Committee on the Environment, Public Health and Food Safety adopted the report by Linda McAVAN (S&D, UK) on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use The committee recommended that Parliament’s position in first reading following the ordinary legislative procedure should amend the Commission proposal as follows: Purpose and scope : an amendment aimed to confirm that homeopathic and registered herbal medicinal should be excluded from the scope of the Regulation. Members also specified that the Regulation determined the pharmacovigilance activities performed at Union level for which fees were due, the amounts and the rules of payment of those fees and the level of remuneration of the Agency, the rapporteurs and the co-rapporteurs. In order to ensure a clear separation between fees paid to Member States and fees paid to the European Medicines Agency, Members stated that Member States should not impose fees for pharmacovigilance tasks that are already covered by the Regulation. Definition of chargeable unit: the Commission proposal had meant that companies would be charged according to the number of different market authorisations they held - and this was calculated down to the size of the pack. Members felt that the number of tablets in a pack was not relevant for pharmacovigilance. It would be more appropriate to charge according to the number of authorisations per active ingredient, and per pharmaceutical form. Annual flat fee : this had been proposed to cover the costs of other pharmacovigilance activities carried out by the Agency, particularly signal detection. Members proposed reducing the amount raised by the EMA, and the scope of the flat fee to cover only the tasks to be undertaken by EMA : Eudravigilance, the Article 57 database, PSUR repository and literature review only, turning the flat fee into a maintenance fee for EMA pharmacovigilance work. To create a level playing field, the reduced annual fee should apply to products with well-established safety profile. Fee reduction : the marketing authorisation holder claiming or having claimed to be entitled to a reduction or an exemption under the Regulation, should submit to the Agency, within seven calendar days from receipt of the Agency's request, the information necessary to demonstrate compliance with the relevant conditions in order for the Agency to be able to verify that those conditions were fulfilled. Fees for safety report : Members felt that the variations were a consequence of periodic safety update assessment, should be seen as an integral part of the entire assessment process and not be charged additionally at national level as no second scientific assessment is required. The committee wanted rapporteurs and co-rapporteurs from Member States to be fairly remunerated, in order to incentivise them to volunteer for the work involved in handling referrals. The corresponding remuneration of the rapporteur and co-rapporteur is 50% of the total fee collected.
  • date: 2014-04-16T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=23897&l=en title: Results of vote in Parliament
  • date: 2014-04-16T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0438 title: T7-0438/2014 summary: The European Parliament adopted by 544 votes to 17, with 11 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use. Parliament adopted its position at first reading following the ordinary legislative procedure. The amendments adopted in plenary are the result of an agreement reached between the European Parliament and the Council. They amended the proposal as follows: Subject matter and scope : Parliament and the Council agreed to adopt this Regulation in order to enable the European Medicines Agency (EMA) to charge fees for those new pharmacovigilance tasks, and pending an overall legislative revision of the fees regimes in the medicinal products sector . This Regulation should establish the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs . Homeopathic and herbal medicinal products and medicinal products which are authorised to be placed on the market in accordance with Article 126a of Directive 2001/83/EC, should be excluded from the scope of this Regulation. Definition of chargeable unit : fees should be levied on all marketing authorisation holders on a fair basis. Therefore, a chargeable unit should be established, irrespective of the procedure under which the medicinal product has been authorised, and of the way in which authorisation numbers are assigned by the Member States or the Commission. That objective is met by establishing the chargeable unit on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof. The active substance(s) should not be taken into account when establishing the chargeable unit in respect of authorised homeopathic medicinal products or authorised herbal medicinal products. Types of fees : it is stipulated that where a fee is levied by the Agency, the Agency shall pay remuneration, to the national competent authorities: for the services provided by the rapporteurs and, where applicable, the co-rapporteurs in the Pharmacovigilance Risk Assessment Committee appointed as members of that Committee by Member States; for the work carried out by the Member States which act as the rapporteurs and, where applicable, co-rapporteurs in the coordination group. Annual fee : for its pharmacovigilance activities relating to information technology systems and the monitoring of selected medical literature, the Agency should levy once per year a fee. The annual fee should be due on 1 July of every year in respect of that calendar year. The amended text emphasises the fact that fees should be established on a basis which takes due account of the ability of small and medium-sized enterprises to pay . Moreover, information on those fees should be publicly available. Where justified, the Commission should adopt delegated acts adjusting the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation. Lastly, any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities.
  • date: 2014-05-08T00:00:00 type: Act adopted by Council after Parliament's 1st reading body: EP/CSL
  • date: 2014-05-15T00:00:00 type: Final act signed body: CSL
  • date: 2014-05-15T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2014-06-27T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products. LEGISLATIVE ACT: Regulation (EU) No 658/2014 of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use. CONTENT: in order to enable the Agency to charge fees for those new pharmacovigilance tasks , and pending an overall legislative revision of the fees regimes in the medicinal products sector, this Regulation has been adopted. The revised 2010 legislation provides for new pharmacovigilance tasks for the Agency, including pharmacovigilance procedures carried out at Union level, the monitoring of literature cases and the improved use of information technology tools. Subject matter and scope : this Regulation shall apply to fees for pharmacovigilance activities relating to medicinal products for human use authorised in the Union and which shall be levied by the European Medicines Agency on marketing authorisation holders. Homeopathic and herbal medicinal products registered in accordance with Directive 2001/83/EC, and medicinal products which are authorised to be placed on the market in accordance with Directive 2001/83/EC, shall be excluded from the scope of this Regulation. This Regulation establishes the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs. Chargeable unit : a chargeable unit is defined on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof. Types of fees : the types of fees charged to marketing authorisation holders are as follows: Fees for the assessment of periodic safety update reports : EUR 19 500 per procedure. From that amount, the remuneration for the rapporteur shall be EUR 13 100. That remuneration shall be shared, where applicable, between the rapporteur and the co-rapporteur(s). Fees for the assessment of post-authorisation safety studies : EUR 43 000 to be paid in two instalments as follows: (a) EUR 17 200 shall be due at the date of the start of the procedure for the assessment of the draft protocol referred to in Directive 2001/83/EC; (b) EUR 25 800 shall be due at the date of the start of the procedure for the assessment of the final study report by the Pharmacovigilance Risk Assessment Committee as referred to in the same Directive. Fees for assessments in the context of referrals initiated as a result of pharmacovigilance data : EUR 179 000 where one or two active substances and/or combinations of active substances are included in the assessment. That fee shall be increased by EUR 38 800 per each additional active substance or combination of active substances as of the third active substance or combination of substances. That fee shall not exceed EUR 295 400 irrespective of the number of active substances and/or combinations of active substances. An annual flat-rate fee of EUR 67 per chargeable unit. This fee is intended to cover the costs of general pharmacovigilance activities of EMA, such as safety data management, literature monitoring and information technology, notably maintenance of the EudraVigilance database. The annual flat fee will be charged as from 1 July 2015 . Reductions and exonerations : small and medium-sized enterprises will benefit of a fee reduction of 40% from all fees covered by the regulation and micro-enterprises are exempted from any fees. Micro enterprises should be exempted from all fees. Generic medicinal products, medicinal products authorised under the provisions relating to well-established medicinal use, authorised homeopathic medicinal products and authorised herbal medicinal products should be subject to a reduced annual fee . Transparency : the fees established in this Regulation should be transparent, fair and proportionate to the work carried out. Information on those fees should be publicly available . Any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities. ENTRY INTO FORCE: 17.07.2014. DELEGATED ACTS: the Commission shall be empowered to adopt delegated acts in order to adjust the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation. The power to adopt delegated acts shall be conferred on the Commission for a period of five years from 17 July 2014 . The European Parliament or the Council may raise objections to a delegated act within a period of two months from the date of notification (this may be extended by two months). If the European Parliament or Council express objections, the delegated act will not enter into force. docs: title: Regulation 2014/658 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658 title: OJ L 189 27.06.2014, p. 0112 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:189:TOC
other
  • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: BORG Tonio
otherinst
  • name: European Economic and Social Committee
  • name: European Committee of the Regions
procedure/Mandatory consultation of other institutions
Economic and Social Committee Committee of the Regions
procedure/Modified legal basis
Old
Rules of Procedure of the European Parliament EP 150
New
Rules of Procedure EP 150
procedure/dossier_of_the_committee
Old
ENVI/7/13158
New
  • ENVI/7/13158
procedure/final/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658
New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658
procedure/other_consulted_institutions
European Economic and Social Committee European Committee of the Regions
procedure/subject
Old
  • 4.20.04 Pharmaceutical products and industry
  • 8.40.08 Agencies and bodies of the EU
New
4.20.04
Pharmaceutical products and industry
8.40.08
Agencies and bodies of the EU
activities/0/docs/0/celexid
CELEX:52013PC0472:EN
activities/0/docs/0/celexid
CELEX:52013PC0472:EN
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf
links/European Commission/title
Old
PreLex
New
EUR-Lex
activities/1/committees/0/rapporteur/0/mepref
Old
4de186960fb8127435bdc09b
New
4f1ad945b819f207b3000009
activities/1/committees/0/shadows/0/mepref
Old
4de182c90fb8127435bdbb26
New
4f1ac61cb819f25efd00001d
activities/2/committees/0/rapporteur/0/mepref
Old
4de186960fb8127435bdc09b
New
4f1ad945b819f207b3000009
activities/2/committees/0/shadows/0/mepref
Old
4de182c90fb8127435bdbb26
New
4f1ac61cb819f25efd00001d
activities/3/committees/0/rapporteur/0/mepref
Old
4de186960fb8127435bdc09b
New
4f1ad945b819f207b3000009
activities/3/committees/0/shadows/0/mepref
Old
4de182c90fb8127435bdbb26
New
4f1ac61cb819f25efd00001d
activities/9/docs
  • url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658 title: Regulation 2014/658
  • url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2014:189:TOC title: OJ L 189 27.06.2014, p. 0112
activities/9/text
  • PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products.

    LEGISLATIVE ACT: Regulation (EU) No 658/2014 of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.

    CONTENT: in order to enable the Agency to charge fees for those new pharmacovigilance tasks, and pending an overall legislative revision of the fees regimes in the medicinal products sector, this Regulation has been adopted. The revised 2010 legislation provides for new pharmacovigilance tasks for the Agency, including pharmacovigilance procedures carried out at Union level, the monitoring of literature cases and the improved use of information technology tools.

    Subject matter and scope: this Regulation shall apply to fees for pharmacovigilance activities relating to medicinal products for human use authorised in the Union and which shall be levied by the European Medicines Agency on marketing authorisation holders.

    Homeopathic and herbal medicinal products registered in accordance with Directive 2001/83/EC, and medicinal products which are authorised to be placed on the market in accordance with Directive 2001/83/EC, shall be excluded from the scope of this Regulation.

    This Regulation establishes the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs.

    Chargeable unit: a chargeable unit is defined on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof.

    Types of fees: the types of fees charged to marketing authorisation holders are as follows:

    • Fees for the assessment of periodic safety update reports: EUR 19 500 per procedure. From that amount, the remuneration for the rapporteur shall be EUR 13 100. That remuneration shall be shared, where applicable, between the rapporteur and the co-rapporteur(s).
    • Fees for the assessment of post-authorisation safety studies: EUR 43 000 to be paid in two instalments as follows: (a) EUR 17 200 shall be due at the date of the start of the procedure for the assessment of the draft protocol referred to in Directive 2001/83/EC; (b) EUR 25 800 shall be due at the date of the start of the procedure for the assessment of the final study report by the Pharmacovigilance Risk Assessment Committee as referred to in the same Directive.
    • Fees for assessments in the context of referrals initiated as a result of pharmacovigilance data: EUR 179 000 where one or two active substances and/or combinations of active substances are included in the assessment. That fee shall be increased by EUR 38 800 per each additional active substance or combination of active substances as of the third active substance or combination of substances. That fee shall not exceed EUR 295 400 irrespective of the number of active substances and/or combinations of active substances.
    • An annual flat-rate fee of EUR 67 per chargeable unit. This fee is intended to cover the costs of general pharmacovigilance activities of EMA, such as safety data management, literature monitoring and information technology, notably maintenance of the EudraVigilance database. The annual flat fee will be charged as from 1 July 2015.

    Reductions and exonerations: small and medium-sized enterprises will benefit of a fee reduction of 40% from all fees covered by the regulation and micro-enterprises are exempted from any fees. Micro enterprises should be exempted from all fees. Generic medicinal products, medicinal products authorised under the provisions relating to well-established medicinal use, authorised homeopathic medicinal products and authorised herbal medicinal products should be subject to a reduced annual fee.

    Transparency: the fees established in this Regulation should be transparent, fair and proportionate to the work carried out. Information on those fees should be publicly available. Any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities.

    ENTRY INTO FORCE: 17.07.2014.

    DELEGATED ACTS: the Commission shall be empowered to adopt delegated acts in order to adjust the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation. The power to adopt delegated acts shall be conferred on the Commission for a period of five years from 17 July 2014. The European Parliament or the Council may raise objections to a delegated act within a period of two months from the date of notification (this may be extended by two months). If the European Parliament or Council express objections, the delegated act will not enter into force.

committees/0/rapporteur/0/mepref
Old
4de186960fb8127435bdc09b
New
4f1ad945b819f207b3000009
committees/0/shadows/0/mepref
Old
4de182c90fb8127435bdbb26
New
4f1ac61cb819f25efd00001d
procedure/final
url
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32014R0658
title
Regulation 2014/658
procedure/subject/1
Old
8.40.08 Community bodies, agencies
New
8.40.08 Agencies and bodies of the EU
activities/9
date
2014-06-27T00:00:00
type
Final act published in Official Journal
procedure/stage_reached
Old
Procedure completed, awaiting publication in Official Journal
New
Procedure completed
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/4/docs/0
url
http://www.europarl.europa.eu/oeil/popups/sda.do?id=23897&l=en
type
Results of vote in Parliament
title
Results of vote in Parliament
activities/4/type
Old
Decision by Parliament, 1st reading/single reading
New
Results of vote in Parliament
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/2/committees/0/shadows/0/group
Old
PPE
New
PPE
activities/3/committees/0/shadows/0/group
Old
PPE
New
PPE
committees/0/shadows/0/group
Old
PPE
New
PPE
activities/1/committees/0/date
2013-07-11T00:00:00
activities/1/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/1/committees/0/shadows
  • group: PPE name: AYUSO Pilar
activities/2/committees/0/date
2013-07-11T00:00:00
activities/2/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/2/committees/0/shadows
  • group: PPE name: AYUSO Pilar
activities/3/committees/0/date
2013-07-11T00:00:00
activities/3/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/3/committees/0/shadows
  • group: PPE name: AYUSO Pilar
committees/0/date
2013-07-11T00:00:00
committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
committees/0/shadows
  • group: PPE name: AYUSO Pilar
activities/1/committees/0/date
2013-07-11T00:00:00
activities/1/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/1/committees/0/shadows
  • group: EPP name: AYUSO Pilar
activities/2/committees/0/date
2013-07-11T00:00:00
activities/2/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/2/committees/0/shadows
  • group: EPP name: AYUSO Pilar
activities/3/committees/0/date
2013-07-11T00:00:00
activities/3/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities/3/committees/0/shadows
  • group: EPP name: AYUSO Pilar
committees/0/date
2013-07-11T00:00:00
committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
committees/0/shadows
  • group: EPP name: AYUSO Pilar
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 150
activities/8
date
2014-05-15T00:00:00
body
EP
type
End of procedure in Parliament
activities/7
date
2014-05-15T00:00:00
body
CSL
type
Final act signed
procedure/stage_reached
Old
Awaiting signature of act
New
Procedure completed, awaiting publication in Official Journal
activities/4/docs/0/text
  • The European Parliament adopted by 544 votes to 17, with 11 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use.

    Parliament adopted its position at first reading following the ordinary legislative procedure. The amendments adopted in plenary are the result of an agreement reached between the European Parliament and the Council. They amended the proposal as follows:

    Subject matter and scope: Parliament and the Council agreed to adopt this Regulation in order to enable the European Medicines Agency (EMA) to charge fees for those new pharmacovigilance tasks, and pending an overall legislative revision of the fees regimes in the medicinal products sector.

    This Regulation should establish the pharmacovigilance activities performed at Union level for which fees are due, the amounts and the rules of payment of those fees to the Agency, and the amounts of remuneration by the Agency for the services provided by the rapporteurs and, where applicable, the co-rapporteurs.

    Homeopathic and herbal medicinal products and medicinal products which are authorised to be placed on the market in accordance with Article 126a of Directive 2001/83/EC, should be excluded from the scope of this Regulation.

    Definition of chargeable unit: fees should be levied on all marketing authorisation holders on a fair basis. Therefore, a chargeable unit should be established, irrespective of the procedure under which the medicinal product has been authorised, and of the way in which authorisation numbers are assigned by the Member States or the Commission.

    That objective is met by establishing the chargeable unit on the basis of the active substance(s) and the pharmaceutical form of the medicinal products that are subject to the obligation to be registered in the database referred to in point (l) of the second subparagraph of Article 57(1) of Regulation (EC) No 726/2004, based on information from the list of all medicinal products authorised in the Union referred to in Article 57(2) thereof.

    The active substance(s) should not be taken into account when establishing the chargeable unit in respect of authorised homeopathic medicinal products or authorised herbal medicinal products.

    Types of fees: it is stipulated that where a fee is levied by the Agency, the Agency shall pay remuneration, to the national competent authorities:

    • for the services provided by the rapporteurs and, where applicable, the co-rapporteurs in the Pharmacovigilance Risk Assessment Committee appointed as members of that Committee by Member States;
    • for the work carried out by the Member States which act as the rapporteurs and, where applicable, co-rapporteurs in the coordination group.

    Annual fee: for its pharmacovigilance activities relating to information technology systems and the monitoring of selected medical literature, the Agency should levy once per year a fee. The annual fee should be due on 1 July of every year in respect of that calendar year.

    The amended text emphasises the fact that fees should be established on a basis which takes due account of the ability of small and medium-sized enterprises to pay. Moreover, information on those fees should be publicly available.

    Where justified, the Commission should adopt delegated acts adjusting the amounts of the fees and the amounts of the remuneration for rapporteurs and co-rapporteurs to take account of inflation.

    Lastly, any future revisions of the pharmacovigilance fees or other fees levied by the Agency should be based on a transparent and independent evaluation of the costs of the Agency and the costs of the tasks carried out by the national competent authorities.

activities/5
date
2014-05-08T00:00:00
body
CSL
type
Council Meeting
council
Foreign Affairs
meeting_id
3311
activities/6
date
2014-05-08T00:00:00
body
EP/CSL
type
Act adopted by Council after Parliament's 1st reading
procedure/stage_reached
Old
Provisional agreement between Parliament and Council on final act
New
Awaiting signature of act
activities/4/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2014-0438
procedure/stage_reached
Old
Awaiting Council 1st reading position / budgetary conciliation convocation
New
Provisional agreement between Parliament and Council on final act
activities/4
date
2014-04-16T00:00:00
docs
type: Decision by Parliament, 1st reading/single reading title: T7-0438/2014
body
EP
type
Decision by Parliament, 1st reading/single reading
procedure/stage_reached
Old
Awaiting Parliament 1st reading / single reading / budget 1st stage
New
Awaiting Council 1st reading position / budgetary conciliation convocation
activities/0
date
2013-06-26T00:00:00
docs
url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf title: COM(2013)0472 type: Legislative proposal published celexid: CELEX:52013PC0472:EN
body
EC
commission
DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
type
Legislative proposal published
activities/0/body
Old
EP
New
EC
activities/0/commission
  • DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
activities/0/date
Old
2014-04-16T00:00:00
New
2013-06-26T00:00:00
activities/0/docs
  • url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf celexid: CELEX:52013PC0472:EN type: Legislative proposal published title: COM(2013)0472
activities/0/type
Old
Vote scheduled
New
Legislative proposal published
activities/4/type
Old
Vote in plenary scheduled
New
Vote scheduled
activities/3/docs/0/text
  • The Committee on the Environment, Public Health and Food Safety adopted the report by Linda McAVAN (S&D, UK) on the proposal for a regulation of the European Parliament and of the Council on fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use

    The committee recommended that Parliament’s position in first reading following the ordinary legislative procedure should amend the Commission proposal as follows:

    Purpose and scope: an amendment aimed to confirm that homeopathic and registered herbal medicinal should be excluded from the scope of the Regulation.

    Members also specified that the Regulation determined the pharmacovigilance activities performed at Union level for which fees were due, the amounts and the rules of payment of those fees and the level of remuneration of the Agency, the rapporteurs and the co-rapporteurs.

    In order to ensure a clear separation between fees paid to Member States and fees paid to the European Medicines Agency, Members stated that Member States should not impose fees for pharmacovigilance tasks that are already covered by the Regulation.

    Definition of chargeable unit: the Commission proposal had meant that companies would be charged according to the number of different market authorisations they held - and this was calculated down to the size of the pack. Members felt that the number of tablets in a pack was not relevant for pharmacovigilance. It would be more appropriate to charge according to the number of authorisations per active ingredient, and per pharmaceutical form.

    Annual flat fee: this had been proposed to cover the costs of other pharmacovigilance activities carried out by the Agency, particularly signal detection.

    Members proposed reducing the amount raised by the EMA, and the scope of the flat fee to cover only the tasks to be undertaken by EMA: Eudravigilance, the Article 57 database, PSUR repository and literature review only, turning the flat fee into a maintenance fee for EMA pharmacovigilance work. 

    To create a level playing field, the reduced annual fee should apply to products with well-established safety profile.

    Fee reduction: the marketing authorisation holder claiming or having claimed to be entitled to a reduction or an exemption under the Regulation, should submit to the Agency, within seven calendar days from receipt of the Agency's request, the information necessary to demonstrate compliance with the relevant conditions in order for the Agency to be able to verify that those conditions were fulfilled.

    Fees for safety report: Members felt that the variations were a consequence of periodic safety update assessment, should be seen as an integral part of the entire assessment process and not be charged additionally at national level as no second scientific assessment is required.

    The committee wanted rapporteurs and co-rapporteurs from Member States to be fairly remunerated, in order to incentivise them to volunteer for the work involved in handling referrals. The corresponding remuneration of the rapporteur and co-rapporteur is 50% of the total fee collected.

activities/4/type
Old
Indicative plenary sitting date, 1st reading/single reading
New
Vote in plenary scheduled
activities/3/docs
  • url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2013-0476&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0476/2013
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/0
date
2013-06-26T00:00:00
docs
body
EC
type
Legislative proposal
commission
DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
activities/0/body
Old
EP
New
EC
activities/0/commission
  • DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
activities/0/date
Old
2013-10-24T00:00:00
New
2013-06-26T00:00:00
activities/0/docs/0/celexid
CELEX:52013PC0472:EN
activities/0/docs/0/text
  • PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products.

    PROPOSED ACT: Regulation of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

    BACKGROUND: the legal framework of pharmacovigilance for medicinal products for human use marketed within the EU is provided for in Regulation (EC) No 726/2004 and in Directive 2001/83/EC.

    Legislation in this area was revised in 2010 through Regulation (EU) No 1235/2010 and Directive 2010/84/EU which strengthen and rationalise the system for safety monitoring of medicines on the European market.

    This legislation is applicable as of July 2012. It provides for a number of EU-wide procedures to assess pharmacovigilance data which may lead to regulatory action. Some additional amendments to the pharmacovigilance legislation were introduced in 2012 with Directive 2012/26/EU following the 'Mediator' case.

    The revised pharmacovigilance legislation significantly widened the tasks of the European Medicines Agency with regard to pharmacovigilance, irrespective of whether the medicinal products have been authorised via the 'centralised procedure' (in accordance with the Regulation) or via national procedures (in accordance with the Directive). The Agency has therefore acquired pharmacovigilance competences also for nationally authorised medicines, in addition to reinforced competences for centrally authorised medicines.

    Other tasks include the monitoring of literature cases, the improved information technology tools and the provision of more information to the general public.

    New categories of fees should therefore be created to cover the new and specific tasks of the Agency.

    IMPACT ASSESSMENT: the Impact Assessment report that accompanies this proposal considered several options, based on estimation of cost.

    A combination of procedure-based fees and an annual flat fee has been considered to be the most transparent, cost-based, activity-based and proportionate way of setting the new fees, in order to cover the cost under the new pharmacovigilance legislation.

    LEGAL BASIS: Article 114 and Article 168(4)(c) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: the proposed Regulation aims at setting high standards of quality and safety for medicinal products as it ensures the availability of sufficient financial resources to perform the pharmacovigilance activities that are necessary to guarantee that high standards are maintained once the product is authorised.

    The revised pharmacovigilance legislation provides for fees to be charged to marketing authorisation holders. These fees should be related to pharmacovigilance activities performed at the level of the EU, notably in the context of the EU-wide assessment procedures. These procedures include scientific assessment carried out by rapporteurs from the national competent authorities of the Member States. These fees are therefore not intended to cover the pharmacovigilance activities of the national competent authorities performed at national level. Member States may accordingly continue to charge fees for the activities performed at national level which should, however, not overlap with the fees laid down in this legal proposal.

    The proposal foresees two separate types of fees:

    • fees for procedures for the assessment of periodic safety update reports, postauthorisation safety studies and pharmacovigilance referrals;
    • an annual flat fee to be charged to marketing authorisation holders having at least one medicinal product that is authorised in the EU and registered in the database provided for in Regulation (EC) No 726/2004. The fee revenue from the annual flat fee shall be retained by the Agency.

    Some fee reductions and fee waivers are foreseen in respect of the proposed fees:

    • reductions for medicinal products for which the marketing authorisation holder is a small or medium-sized enterprise would be granted for all types of fees. Micro enterprises would be exempted from all fees;
    • a reduction of the annual flat fee is therefore proposed for authorised generic, homeopathic and herbal medicinal products and for medicinal products authorised on grounds of well-established medical use. However, where these medicinal products are included in the Union-wide pharmacovigilance procedures, the full fees for procedures would apply.

    Marketing authorisation holders would be charged as follows:

    • marketing authorisation holders having at least one product involved in a Unionwide pharmacovigilance procedure would be charged a fee for procedures,
    • marketing authorisation holders in the EU, with the exceptions explained above, would be charged the annual flat fee.

    Fees referred to in this Regulation should be transparent, fair and proportionate to the work carried out.

    In line with the recommendations of the European Court of Auditors and the European Parliament, it is proposed that rapporteurs from the national competent authorities of the Member States be remunerated according to a fixed scale based on estimations of cost.

    BUDGETARY IMPLICATION: all options of legislative action, including the option which underpins this proposal, were based on the assumption that the costs related to pharmacovigilance would be covered through fees.

    Therefore, no impact on the EU general budget is foreseen in the accompanying financial statement of this proposal.

    DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in in accordance with Article 290 of the Treaty on the Functioning of the European Union.

activities/0/docs/0/title
Old
PE519.514
New
COM(2013)0472
activities/0/docs/0/type
Old
Committee draft report
New
Legislative proposal published
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf
activities/0/type
Old
Committee draft report
New
Legislative proposal published
activities/2
date
2013-10-16T00:00:00
docs
url: http://eescopinions.eesc.europa.eu/eescopiniondocument.aspx?language=EN&docnr=5169&year=2013 type: Economic and Social Committee: opinion, report title: CES5169/2013
body
ESOC
type
Economic and Social Committee: opinion, report
activities/4
date
2013-11-11T00:00:00
docs
url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004 type: Amendments tabled in committee title: PE523.004
body
EP
type
Amendments tabled in committee
activities/6
date
2013-12-20T00:00:00
body
EP
type
Committee report tabled for plenary, 1st reading/single reading
committees
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament 1st reading / single reading / budget 1st stage
activities/5/committees
  • body: EP shadows: group: EPP name: AYUSO Pilar responsible: True committee: ENVI date: 2013-07-11T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda
  • body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO
  • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
activities/5/type
Old
Vote scheduled in committee, 1st reading/single reading
New
Vote in committee, 1st reading/single reading
procedure/Modified legal basis
Rules of Procedure of the European Parliament EP 138
activities/2/docs/0/celexid
CELEX:52013AE5169:EN
activities/2/docs/0/celexid
CELEX:52013AE5169:EN
activities/2/docs/0/url
http://eescopinions.eesc.europa.eu/eescopiniondocument.aspx?language=EN&docnr=5169&year=2013
activities/2
date
2013-10-16T00:00:00
docs
type: Economic and Social Committee: opinion, report title: CES5169/2013
body
ESOC
type
Economic and Social Committee: opinion, report
activities/3/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE523.004
activities/3
date
2013-11-11T00:00:00
docs
type: Amendments tabled in committee title: PE523.004
body
EP
type
Amendments tabled in committee
activities/2/date
Old
2013-10-18T00:00:00
New
2013-10-24T00:00:00
activities/2/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE519.514
activities/2
date
2013-10-18T00:00:00
docs
type: Committee draft report title: PE519.514
body
EP
type
Committee draft report
activities/1/committees/0/shadows
  • group: EPP name: AYUSO Pilar
committees/0/shadows
  • group: EPP name: AYUSO Pilar
activities/2
date
2013-12-17T00:00:00
body
EP
type
Vote scheduled in committee, 1st reading/single reading
activities/3
date
2014-04-16T00:00:00
body
EP
type
Indicative plenary sitting date, 1st reading/single reading
activities/0/docs/0/text
  • PURPOSE: to contribute to the well-functioning of the internal market and the common post-marketing surveillance of medicinal products.

    PROPOSED ACT: Regulation of the European Parliament and of the Council.

    ROLE OF THE EUROPEAN PARLIAMENT: the European Parliament decides in accordance with the ordinary legislative procedure and on an equal footing with the Council.

    BACKGROUND: the legal framework of pharmacovigilance for medicinal products for human use marketed within the EU is provided for in Regulation (EC) No 726/2004 and in Directive 2001/83/EC.

    Legislation in this area was revised in 2010 through Regulation (EU) No 1235/2010 and Directive 2010/84/EU which strengthen and rationalise the system for safety monitoring of medicines on the European market.

    This legislation is applicable as of July 2012. It provides for a number of EU-wide procedures to assess pharmacovigilance data which may lead to regulatory action. Some additional amendments to the pharmacovigilance legislation were introduced in 2012 with Directive 2012/26/EU following the 'Mediator' case.

    The revised pharmacovigilance legislation significantly widened the tasks of the European Medicines Agency with regard to pharmacovigilance, irrespective of whether the medicinal products have been authorised via the 'centralised procedure' (in accordance with the Regulation) or via national procedures (in accordance with the Directive). The Agency has therefore acquired pharmacovigilance competences also for nationally authorised medicines, in addition to reinforced competences for centrally authorised medicines.

    Other tasks include the monitoring of literature cases, the improved information technology tools and the provision of more information to the general public.

    New categories of fees should therefore be created to cover the new and specific tasks of the Agency.

    IMPACT ASSESSMENT: the Impact Assessment report that accompanies this proposal considered several options, based on estimation of cost.

    A combination of procedure-based fees and an annual flat fee has been considered to be the most transparent, cost-based, activity-based and proportionate way of setting the new fees, in order to cover the cost under the new pharmacovigilance legislation.

    LEGAL BASIS: Article 114 and Article 168(4)(c) of the Treaty on the Functioning of the European Union (TFEU).

    CONTENT: the proposed Regulation aims at setting high standards of quality and safety for medicinal products as it ensures the availability of sufficient financial resources to perform the pharmacovigilance activities that are necessary to guarantee that high standards are maintained once the product is authorised.

    The revised pharmacovigilance legislation provides for fees to be charged to marketing authorisation holders. These fees should be related to pharmacovigilance activities performed at the level of the EU, notably in the context of the EU-wide assessment procedures. These procedures include scientific assessment carried out by rapporteurs from the national competent authorities of the Member States. These fees are therefore not intended to cover the pharmacovigilance activities of the national competent authorities performed at national level. Member States may accordingly continue to charge fees for the activities performed at national level which should, however, not overlap with the fees laid down in this legal proposal.

    The proposal foresees two separate types of fees:

    • fees for procedures for the assessment of periodic safety update reports, postauthorisation safety studies and pharmacovigilance referrals;
    • an annual flat fee to be charged to marketing authorisation holders having at least one medicinal product that is authorised in the EU and registered in the database provided for in Regulation (EC) No 726/2004. The fee revenue from the annual flat fee shall be retained by the Agency.

    Some fee reductions and fee waivers are foreseen in respect of the proposed fees:

    • reductions for medicinal products for which the marketing authorisation holder is a small or medium-sized enterprise would be granted for all types of fees. Micro enterprises would be exempted from all fees;
    • a reduction of the annual flat fee is therefore proposed for authorised generic, homeopathic and herbal medicinal products and for medicinal products authorised on grounds of well-established medical use. However, where these medicinal products are included in the Union-wide pharmacovigilance procedures, the full fees for procedures would apply.

    Marketing authorisation holders would be charged as follows:

    • marketing authorisation holders having at least one product involved in a Unionwide pharmacovigilance procedure would be charged a fee for procedures,
    • marketing authorisation holders in the EU, with the exceptions explained above, would be charged the annual flat fee.

    Fees referred to in this Regulation should be transparent, fair and proportionate to the work carried out.

    In line with the recommendations of the European Court of Auditors and the European Parliament, it is proposed that rapporteurs from the national competent authorities of the Member States be remunerated according to a fixed scale based on estimations of cost.

    BUDGETARY IMPLICATION: all options of legislative action, including the option which underpins this proposal, were based on the assumption that the costs related to pharmacovigilance would be covered through fees.

    Therefore, no impact on the EU general budget is foreseen in the accompanying financial statement of this proposal.

    DELEGATED ACTS: the proposal contains provisions empowering the Commission to adopt delegated acts in in accordance with Article 290 of the Treaty on the Functioning of the European Union.

activities/1/committees/0/date
2013-07-11T00:00:00
activities/1/committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
committees/0/date
2013-07-11T00:00:00
committees/0/rapporteur
  • group: S&D name: MCAVAN Linda
activities
  • date: 2013-06-26T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2013/0472/COM_COM(2013)0472_EN.pdf celexid: CELEX:52013PC0472:EN type: Legislative proposal published title: COM(2013)0472 url: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0234:FIN:EN:PDF type: Document attached to the procedure title: SWD(2013)0234 url: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=SWD:2013:0235:FIN:EN:PDF type: Document attached to the procedure title: SWD(2013)0235 type: Legislative proposal body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
  • date: 2013-07-01T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
committees
  • body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI
  • body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO
  • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
links
National parliaments
European Commission
other
  • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: BORG Tonio
procedure
dossier_of_the_committee
ENVI/7/13158
reference
2013/0222(COD)
Mandatory consultation of other institutions
Economic and Social Committee Committee of the Regions
subtype
Legislation
legal_basis
stage_reached
Awaiting committee decision
instrument
Regulation
title
Medicinal products for human use: fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities
type
COD - Ordinary legislative procedure (ex-codecision procedure)
subject